$PALI 0.56 Developing
- Date
- Jun 29, 2026
- Mentions
- 1
- Unique authors
- 1
- Sector
- biotech
- Stance
- neutral
- On card
- no
Sentiment history
bullish
neutral
mixed
bearish
line = signal
dashed = price
No sentiment history available for $PALI yet.
Sentiment
neutral 1
Notable posts
-
neutral 42 eng
Palisade Bio $PALI said the FDA cleared its IND for PALI-2108, allowing a global Phase 2 trial in ulcerative colitis. The ASCENTRA-UC study is expected to enroll ~204 patients and test 15 mg and 30 mg once-daily doses vs. placebo. Enrollment is expected in H2 2026, with primary efficacy results expected in H2 2027.
view on X →
Only one day of history so far — the signal arc fills in as the daily job runs.